Rationale: The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL) triggers lysosomal degradation of the low-density lipoprotein receptor. The tissue-specific effects of the IDOL pathway on plasma cholesterol and atherosclerosis have not been examined.
T he E3 ligase inducible degrader of the low-density lipoprotein receptor (IDOL) ubiquitinates and facilitates lysosomal degradation of the low-density lipoprotein receptor (LDLR). 1 IDOL expression is controlled by the sterol-responsive liver X receptor (LXR) nuclear receptors. In response to elevated cellular cholesterol levels, LXRs induce IDOL expression, thereby causing degradation of the LDLR and inhibiting additional cholesterol uptake by the cell. The LXR-IDOL pathway provides a complementary mechanism to the sterol regulatory element-binding proteins for feedback regulation of LDL uptake by sterols. We have identified the molecular basis for IDOL target recognition and shown that loss of IDOL expression in cells alters LDLR protein levels and cholesterol uptake. 2, 3 However, the tissue-specific effects of the IDOL pathway on plasma cholesterol levels and cardiovascular disease are unknown. The ability of IDOL to affect atherosclerosis development in mice has not been addressed previously.
Human genetic studies support a link between the activity of the LXR-IDOL pathway and plasma lipid levels. Genomewide association studies have identified noncoding variants within IDOL that are associated with LDL cholesterol levels. 4 In addition, a coding single nucleotide polymorphism in IDOL, N342S, was associated with lower plasma cholesterol levels in Mexicans. 5 Most recently, a complete loss-of-function IDOL allele was reported to be associated with low LDL levels. 6 The importance of the LDLR in the regulation of plasma cholesterol levels is well established. Loss-of-function LDLR mutations in humans reduce hepatic LDL clearance, elevate plasma LDL levels, and accelerate atherosclerosis. 7 Moreover, the LDLR knockout mouse is one of the most widely used models of hypercholesterolemia and atherosclerosis. The relative contribution of LDLR deletion in specific tissues to hypercholesterolemia and atherosclerosis in these mice has not been defined. Because the liver is the key organ for the uptake of LDL cholesterol, we sought to examine the consequence of chronic liver-specific expression of a dominant-active form of IDOL in mice. Our results show that chronic stable expression of IDOL effectively reduces hepatic LDLR protein levels and raises plasma LDL cholesterol levels and that this effect is durable over the life of the animal. Liver-selective IDOL transgenic mice are a robust, dominantly inherited, diet-inducible model for the study of atherosclerosis.
Methods
An expanded methods section is available in the online-only Data Supplement.
Mice
Briefly, mice were generated expressing a dominant-active form of IDOL (K293R, K309R, K310R, K320R) known as super IDOL (sIDOL) under the direction of the albumin enhancer/promoter. At 6 weeks of age, liver-specific sIDOL transgene (L-sIDOL) mice and their wild-type (WT) littermates were fed a Western diet (WD; 21% fat 0.21% cholesterol; Research Diets) or maintained on a chow diet for 20 or 30 weeks as indicated. LDLR knockout mice and apolipoprotein E (ApoE)*3 Leiden mice were placed on a WD from 6 weeks of age for 20 weeks. All mice were maintained on a 12-hour light/dark cycle and had access to food and water ad libitum. Mice were fasted for 6 hours before euthanization. Animal studies were performed in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and the University of California, Los Angeles Animal Research Committee guidelines. Lesion area was quantified by en face and aortic root analysis.
Results

Generation of L-sIDOL Transgenic Mice
The E3 ubiquitin ligase IDOL is a potent post-transcriptional modifier of LDLR protein levels. In addition to targeting the LDLR for lysosomal degradation, IDOL also targets itself for proteasomal degradation through autoubiquitination. We previously identified lysine residues in the IDOL FERM domain critical for IDOL autoubiquitination and stability. An IDOL mutant lacking these residues (K293R, K309R, K310R, K320R) is unable to undergo autoubiquitination but maintains its ability to degrade the LDLR. 2 We generated transgenic mice expressing this degradation-resistant, dominant-active form of human IDOL (sIDOL) in C57Bl/6J mice from the liver-specific albumin promoter (L-sIDOL transgenic mice; Figure 1A ). Real-time polymerase chain reaction analysis confirmed that transgene expression was selective for liver ( Figure 1B reduction in hepatic LDLR protein expression, confirming increased IDOL activity ( Figure 1C ). We chose to perform subsequent studies on line no. 1 because this line was associated with slightly more hepatic LDLR degradation and higher plasma cholesterol levels than line no. 2 ( Figure 1C and 1D). As expected, there was no change in LDLR mRNA, consistent with the role of IDOL as a post-translational modifier of LDLR protein levels ( Figure 1E ). L-sIDOL mice and their littermate controls were fed chow or WD for 20 or 30 weeks. There was no difference in body or liver weight between WT mice and L-sIDOL mice within their respective age or diet groups (Table; Online Table I ). WD feeding was associated with increased weight gain across all groups at both time points. Male L-sIDOL mice showed a small reduction in hepatic fat mass as assessed by ex vivo MRI, consistent with reduced hepatic lipid uptake (P<0.05; Figure 2A ). L-sIDOL expression did not cause overt hepatotoxicity because plasma alanine aminotransferase was not different from WT controls on chow or WD ( Figure 2B ). There was no significant difference in mouse IDOL or ATPbinding cassette transporter AI mRNA expression in the liver between WT and L-sIDOL transgenic mice across all groups ( Figure 2C ). Thus, the sIDOL transgene does not seem to provoke a compensatory response in the activity of the endogenous LXR pathway in the liver.
Stable Expression of IDOL in Mouse Liver Raises Plasma LDL Cholesterol Levels
Plasma cholesterol levels were markedly elevated in L-sIDOL mice not only in association with a WD but even on a chow diet ( Figure 3A and 3B). This effect was even more profound after 30 weeks (P<0.001). However, L-sIDOL mice did not develop hypercholesterolemia to the level seen in LDLR knockout mice on WD, likely reflecting either residual hepatic LDLR expression or preserved peripheral LDLR expression, in L-sIDOL mice (P<0.001; Figure 7C ). High-performance liquid chromatography profiling of plasma lipid distribution revealed that the increase in cholesterol could be attributed primarily to an increase in the LDL fraction ( Figure 3D and 3G). Consistent with the high-performance liquid chromatographic data, we observed increased expression of ApoB protein levels in both chow and WD-fed L-sIDOL mice by immunoblotting ( Figure 3C and 3F). In contrast to LDL cholesterol, we observed little difference in high-density lipoprotein cholesterol fractions as assessed by high-performance liquid chromatography profiling ( Figure 3D and 3G), and there was no difference apolipoprotein A-I protein expression ( Figure 3C and 3F). Interestingly, chow-fed male L-sIDOL mice showed a reduction in the very-low-density lipoprotein triglyceride levels compared with WT, but this difference was not observed in females or when the mice were fed WD ( Figure 3E and 3H; Table; Online Table I ). Similar to LDLR knockout mice, L-sIDOL mice exhibited elevated plasma triglyceride levels in the very-low-density lipoprotein and LDL fractions compared with WT littermates when maintained on WD (Table; Online Table I ; Figure 3H ), although these values were not elevated to the levels seen in LDLR knockout mice (Table) .
Stable Expression of IDOL in Mouse Liver Promotes Atherosclerosis
To determine the impact of chronic expression of IDOL and the consequent downregulation of hepatic LDLR protein on the development of cardiovascular disease, we analyzed atherosclerosis with both en face and aortic root section approaches. En face analysis after 20 weeks on WD revealed substantial lesion development in the aortas of L-sIDOL mice, whereas WT controls developed no detectable lesions at this time point ( Figure 4A and 4B) . The extent of lesions in L-sIDOL mice was further enhanced when they were maintained on WD for 30 weeks. Interestingly, lesion formation in L-sIDOL mice was highly diet dependent because only minimal lesions were seen on chow diet ( Figure 4A and 4B) . We observed similar effects of L-sIDOL expression on atherosclerosis development in the aortic root ( Figure 5A ). L-sIDOL mice had a marked increased in lesion area compared with the negligible lesion development in WT mice (P<0.001). Hemotoxylin and eosin suggested that some lesions were beginning to develop an acellular core ( Figure 5B, top) . Trichrome staining further revealed collagen deposition in lesions of L-sIDOL mice (Figure 5B, bottom) . Immunohistochemical staining for CD68 confirmed that the lesions formed in L-sIDOL aortas were macrophage rich (Figure 5B apoptosis inhibitor expressed in macrophages, consistent with increased sterols within the vessel wall of the lesion-rich transgenic mice ( Figure 6 ). We also observed an upregulation in inflammatory genes, including the p65 subunit of nuclear factor-κB, relA (v-rel avian reticuloendotheliosis viral oncogene homolog A [p65]), as well as the proatherogenic vascular cell adhesion molecule-1 ( Figure 6 ). Increased scavenger receptor A was also observed, consistent with increased macrophage content ( Figure 6 ).
Because the L-sIDOL mice represent a new monoallelic mouse model of atherogenesis, we compared plasma lipid levels and lesion development between L-sIDOL mice and 2 widely used mouse models, LDLR knockout mice and ApoE*3 Leiden mice. In comparison with LDLR knockout mice, the phenotype of L-sIDOL mice is less severe, both in terms of the degree of plasma LDL cholesterol elevation and the extent of lesion development by en face and root section analysis ( Figure 7A-7C ). The higher LDL cholesterol levels in LDLR knockout mice, despite the severely reduced hepatic LDLR protein levels in L-sIDOL mice, are suggestive of a significant role for extrahepatic LDLR in LDL clearance in this setting. We also compared L-sIDOL mice with female ApoE*3 Leiden mice because lesion development is reported to be greatest in females in this strain as a result of higher cholesterol and triglyceride levels than in males. 8 When both L-sIDOL and ApoE*3 Leiden mice were fed WD for 20 weeks, L-sIDOL transgenic mice developed substantially more lesions as assessed by both en face and aortic root section analysis ( Figure 7D and 7E) . Plasma total and LDL cholesterol levels were comparable between L-sIDOL and ApoE*3 Leiden mice on WD (L-sIDOL: 11.87±1.16 mmol/L [n=10]; E3L: 13.28±0.63 mmol/L [n=8]; Figure 7F ). Thus, L-sIDOL mice fed WD developed more severe atherosclerosis, despite similar plasma cholesterol levels. Consistent with the ApoE mutation, however, ApoE*3 Leiden mice had higher levels of very-lowdensity lipoprotein cholesterol compared with L-sIDOL mice.
In summary, chronic stable expression of IDOL in mouse liver is sufficient to durably increase plasma LDL cholesterol levels and promote substantial atherosclerotic lesion formation. Atherosclerosis development in L-sIDOL mice is robust for a transgenic mouse on the C57BL/6J background in the absence of a concurrent genetic lesion in LDLR or ApoE. Furthermore, lesion formation in this model does not require the addition of cholate to the diet.
Discussion
We have shown here that chronically increased hepatic IDOL activity results not only in elevated plasma cholesterol levels but also marked atherosclerotic lesion deposition on a WD. Our data indicate that dominant activation of the IDOL pathway in the mouse liver can override other LDLR regulatory pathways leading to cardiovascular disease.
Prior work has established that susceptibility to atherosclerosis differs markedly between mouse strains. 9 In C57Bl/6 mice, there seems to be a threshold above which atherosclerosis development is observed. In our study, feeding C57Bl/6J mice WD raised plasma cholesterol levels to a measureable degree, but we observed virtually no lesion development. Introduction of the L-sIDOL transgene further increased plasma cholesterol levels in response to WD feeding and this resulted in substantial lesion formation. Interestingly, although the plasma cholesterol levels in L-sIDOL mice on WD are below those of LDLR knockout mice, they are clearly above the threshold for lesion development because we observe robust atherosclerosis in the aortic arch. The lower cholesterol levels seen in L-sIDOL mice compared with LDLR knockout mice may be because of low level residual hepatic LDLR expression in L-sIDOL transgenic mice; however, it is also possible that extrahepatic LDLR expression contributes meaningfully to LDL clearance in a setting in which hepatic LDLR expression is lost. No tissuespecific knockout models of the LDLR exist, so this has not been directly addressed; however, some studies have suggested a role for intestinal LDLR in systemic cholesterol regulation. 10 There are several advantages to a monoallelic transgenic mouse model for the study of atherosclerosis. Most importantly, the breeding strategy required to generate a compound mutant is greatly simplified, saving both time and money. L-sIDOL mice represent an attractive new model to test the effect of other transgenic or knockout alleles on atherosclerosis. Lesion deposition in L-sIDOL mice is highly dependent on diet, with few lesions being observed in chow-fed mice. In this respect, L-sIDOL mice are similar to LDLR knockout mice but different from ApoE knockout mice. 11 The fact that lesion deposition is driven by diet makes L-sIDOL mice an attractive model system. It is also notable that L-sIDOL mice develop substantial atherosclerotic lesion formation on standard WD formulation (41% calories from fat, 0.2% cholesterol). Unlike what has been reported for some other monoallelic atherosclerosis models, L-sIDOL mice do not require high levels of dietary cholesterol or the addition of cholate to induce lesion formation. 12 Also, because the LDLR is still genetically present in L-sIDOL mice, pathways that affect LDLR expression or function could potentially still be studied with this model.
A further advantage of the L-sIDOL mice is the greater similarity of the lipid profile to humans compared with other mouse models. In contrast to some other transgenic models of hypercholesterolemia, L-sIDOL mice carry the majority of their cholesterol in the LDL fraction and thus represent a more humanized model. L-sIDOL mice are distinct from ApoE knockout mice and ApoE*3 Leiden mice, which carry much of their cholesterol in the very-low-density lipoprotein fraction, a profile that is not seen in humans. 8, 13 ApoE*3 Leiden mice have been bred with CETP (cholesteryl esterl transfer protein) transgenic mice to exhibit or a more humanized lipid profile 14 ; however, a complex breeding strategy is required to introduce the transgenic alleles into a transgenic or knockout line of interest. We observed substantially greater lesion formation in L-sIDOL mice in a direct comparison to ApoE*3 Leiden mice after 20 weeks of WD feeding. Most published studies using ApoE*3 Leiden mice have used more extreme diets, typically containing 0.5% to 1.0% wt/wt cholesterol. Many studies also included 0.1% to 0.5% cholate to increase the absorption of fat and cholesterol. 15 A smaller number of studies have used diets comparable to the WD used here. 14, 16 The majority of lesions observed in the aortic root of L-sIDOL mice are early lesions comprised primarily of foam cells and smooth muscle cells, with some, such as that shown in Figure 5 , beginning to develop an acellular core. We have not observed the highly advanced lesions that can be observed with the LDLR knockout or ApoE knockout models. Thus, at the present time, our model, like the ApoE*3 Leiden model, seems best suited to the study of early lesion formation. It remains possible that more extreme dietary feeding protocols might further enhance lesion severity and complexity in L-sIDOL mice, and we are actively testing alternate regimens. Westerterp et al 14 demonstrated that although ApoE*3 Leiden mice can develop complex lesions, the vast majority of lesions observed were early lesions comprised fatty streaks and foam cells. 16 ApoE*3 Leiden mice must be crossed with hCETP (human cholesteryl ester transfer protein) transgenic mice to develop severe lesions on a WD. 14, 16 Interestingly, although it is difficult to compare lesion quantifications performed in different laboratories, prior studies have estimated the total atherosclerotic burden in the aortic root of ApoE*3 Leiden mice to be ≈50 000 μm 2 after 19 weeks on a WD. 14, 16 These findings are in excellent agreement with our quantification of the ApoE*3 Leiden mice on 20 weeks of WD, which showed a mean total lesion area of ≈47 000 μm 2 .
In summary, hepatic expression of dominant-active IDOL results in diet-induced hypercholesterolemia and atherosclerotic lesion deposition. These data establish that increased activity of the IDOL pathway in the liver can override other LDLR regulatory mechanisms and result in cardiovascular disease. In addition, we anticipate that L-sIDOL mice will prove to be a valuable tool for the study of atherosclerosis development in transgenic and knockout models.
